medigraphic.com
ISSN 0028-3851 (Print)

2021, Number 1

<< Back Next >>

Rev Neurol Neurocir Psiquiat 2021; 49 (1)

Cannabis, health and society

Souza MM

Language: Spanish
References: 67
Page: 23-36
PDF size: 214.74 Kb.


ABSTRACT

Definition and description: The relationship between Cannabis use and individual-family-social affectation. The characteristics of the psychotropic, its alterations and the medicinal use attributed to its synthetic derivatives, whose commercial fashion of great benefits, do not have the approval of regulatory bodies. Epidemiology: Provides a panoramic view of the scope of consumption. Acute/chronic effects: demystify their safety, especially in the long term and point to health consequences. The combination with other psychotropics, disorders and dependence create comorbidity (dual pathology) of greater severity and more difficult management. It stands out for its use in pregnancy and circumstances inappropriate for its elimination. Clinical evaluation: documents the condition, circumstances and alterations required for acute/long-term management. Its actions have means and elements linked to the different programs available. Rehabilitation: recommended by experts meets the individual characteristics and actions necessary for its consolidation. Prevention: establishes international recommendations for different groups of users. Conclusion: Shows the initial and indiscriminate use of Cannabis –inducer of other drug use– and points to the ignorance and prejudices had in a poorly informed society that considers it "safe or curative". The debate should choose between toxicity and damage vs. prevention and health. Adequate pre-consumption information, the provision of truthful data, institutional support and reorientation to the means to improve social health is lacking.


REFERENCES

  1. Souza y MM. Cannabis y salud: del mito a la evidencia. México: Editorial Alfil; 2017.

  2. WHO. World Health Organization, Substance abuse. Cannabis facts. [Acceso junio de 2020] Available in: https://www.who.int/substance_abuse/facts/Cannabis/en/.

  3. U.S. National Institute on Drug Abuse. NIDA. Cannabis: facts for teens. Rockville: National Institutes of Health. Available in: https://www.Drugabuse.gov/publications/Cannabis-facts-teens/want-to-know-more-some-faqs-about-Cannabis.

  4. Inter-American Drug Abuse Control Commission (CICAD), Organization of American States (OAS), Report on Drug Use in the Americas 2019. Washington D.C.: 2019. Available in: www.cicad.oas.org/main/ pubs/Report%20on%20Drug.

  5. Arnold JC. Handbook of cannabis and related pathologies. Cambridge: Academic; 2017. The interactive nature of cannabis and schizophrenia risk genes; pp. 335-344.

  6. World Drug Report 2019. United Nations publication, Sales No. E.19.XI.8. Available in: https://wdr.unodc.org/wdr2019/prelaunch/WDR19_Booklet_2_drug_demand.pdf.

  7. Clark TB. The medical cannabis debate. Compliance Corner. Wolters Kluwer Financial Services. 2015 [Acceso junio de 2020].

  8. Dhillon U. The 2018 National Drug Threat Assessment (NDTA) DEAIntelPublications@usdoj.gov. Available in: https://www.dea.gov/sites/default/files/2018-11/DIR-03218%202018%20NDTA%

  9. U.S. Department of Health and Human Services. Cannabis use in adolescents. 2019. [Acceso junio de 2020] Available in: www.hhs.gov/ash/oah/adolescent-development/substanceuse/Cannabis/index. html.

  10. Duperrouzel JC, Granja K, Pacheco-Colón I, Gonzalez R. Adverse effects of cannabis use on neurocognitive functioning: a systematic review of meta-analytic studies. J Dual Diagn. 2020; 16 (1): 43-57. doi: 10.1080/15504263.2019.1626030.

  11. US Drug Enforcement Administration. Preventing Cannabis use among youth and young adults. Available in: www.dea.gov/sites/default/files/2018-07/DEA-Cannabis-Prevention-2017 online.pdf.

  12. Gobbi G, Atkin T, Zytynski T et al. Association of cannabis use in adolescence and risk of depression, anxiety, and suicidality in young adulthood: a systematic review and meta-analysis. JAMA Psychiatry. 2019; 76 (4): 426-434.

  13. Merikangas KR, Swanson SA. Comorbidity in anxiety disorders. Curr Top Behav Neurosci. 2010; 2: 37-59.

  14. Kessler RC, Ruscio AM, Shear K, Wittchen HU. Epidemiology of anxiety disorders. Curr Top Behav Neurosci. 2010; 2: 21-35.

  15. Drenckhan I, Glöckner-Rist A, Rist F et al. Dimensional structure of bodily panic attack symptoms and their specific connections to panic cognitions, anxiety sensitivity and claustrophobic fears. Psychol Med. 2015; 45 (8): 1675-1685. doi: 10.1017/S0033291714002803.

  16. Meuret AE, Kroll J, Ritz T. Panic disorder comorbidity with medical conditions and treatment implications. Annu Rev Clin Psychol. 2017; 13: 209-240. doi: 10.1146/annurev-clinpsy-021815-093044.

  17. Meuret AE, Tunnell N, Roque A. Anxiety disorders and medical comorbidity: treatment implications. Adv Exp Med Biol. 2020; 1191: 237-261. doi: 10.1007/978-981-32-9705-0_15.

  18. Hettema JM, Verhulst B, Chatzinakos C et al. Genome-wide association study of shared liability to anxiety disorders in Army STARRS. Am J Med Genet B Neuropsychiatr Genet. 2020; 183 (4): 197-207. doi: 10.1002/ajmg.b.32776.

  19. Hamilton I, Monaghan M. Cannabis and psychosis: are we any closer to understanding the relationship? Curr Psychiatry Rep. 2019; 21 (7): 48. doi: 10.1007/s11920-019-1044-x.

  20. Ortiz-Medina MB, Perea M, Torales J et al. Cannabis consumption and psychosis or schizophrenia development. Int J Soc Psychiatry. 2018; 64 (7): 690-704. doi: 10.1177/0020764018801690.

  21. Chandra S, Radwan MM, Majumdar CG, Church JC, Freeman TP, ElSohly MA. New trends in cannabis potency in USA and Europe during the last decade (2008-2017). Eur Arch Psychiatry Clin Neurosci. 2019; 269 (1): 5-15. doi: 10.1007/s00406-019-00983-5.

  22. Souza y MM. Adicciones. Visión integral de sus problemas, enfoque y terapéutica. Patología dual. Facultad de Medicina, UNAM. México: Editorial Prado; 2014.

  23. Karcher NR, Barch DM, Demers CH et al. Genetic predisposition vs individual-specific processes in the association between psychotic-like experiences and cannabis use. JAMA Psychiatry. 2019; 76 (1): 87-94. doi: 10.1001/jamapsychiatry.2018.2546.

  24. Di Forti M, Quattrone D, Tripoli G, La Cascia C et al. Some of the individual differences in risk to develop psychosis among Cannabis users can be explained by where they live and by their age at first use. Schizophr Bull. 2018; 44 (Supl 1): S110. doi: 10.1093/schbul/sby015.272.

  25. Arterberry BJ, Padovano HT, Foster KT, Zucker RA et al. Higher average potency across the U.S. is associated with progression to first Cannabis use disorder symptom. Drug Alcohol Depend. 2019; 195: 186-192. doi: 10.1016/j.drugalcdep.2018.11.012.

  26. Colizzi M, Murray R. Cannabis and psychosis: what do we know and what should we do? Br J Psychiatry. 2018; 212 (4): 195-196. doi: 10.1192/bjp.2018.1.

  27. Grewal RS, George TP. Cannabis-induced psychosis: a review. Psychiatric Times. 2017. [Acceso junio de 2020] Available in: www.psychiatrictimes.com/substance-use-disorder/Cannabisinduced-psycosis-review

  28. Marshall K, Gowing L, Ali R, Le Foll B. Pharmacotherapies for cannabis dependence. Cochrane Database Syst Rev. 2014; 12 (12): CD008940.

  29. Berry K, Palmer T, Gregg L, Barrowclough C, Lobban F. Attachment and therapeutic alliance in psychological therapy for people with recent onset psychosis who use cannabis. Clin Psychol Psychother. 2018; 25 (3): 440-445. doi: 10.1002/cpp.2178.

  30. American College of Obstetricians & Gynecologists. Cannabis Use During Pregnancy and Lactation. 2017. Available in: www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinio-ns/Committee-on-obstetric Practice/Cannabis-use-During-Pregnancy-and-Lactation

  31. Hall KE, Monte AA, Chang T et al. Mental health-related emergency department visits associated with Cannabis in Colorado. Acad Emerg Med. 2018; 25 (5): 526-537.

  32. Abdel-Salam OME, Galal AF, Elshebiney SA, Gaafar AEDM. International aspects of cannabis use and misuse: Egypt. In: Preedy V. Handbook of cannabis and related pathologies: biology, pharmacology, diagnosis, and treatment. Academic Press, Elsevier Science Publishing Co Inc.; 2017. pp. 505-516.

  33. Jacobus J, Tapert SF. Effects of cannabis on the adolescent brain. Curr Pharm Des. 2014; 20 (13): 2186-2193. doi: 10.2174/13816128113199990426.

  34. Wadsworth E, Hammond D. International differences in patterns of cannabis use among youth: prevalence, perceptions of harm, and driving under the influence in Canada, England & United States. Addict Behav. 2019; 90: 171-175.

  35. Hall W, Degenhardt L. The adverse health effects of chronic cannabis use. Drug Test Anal. 2014; 6 (1-2): 39-45. doi: 10.1002/dta.1506.

  36. Winiger EA, Huggett SB, Hatoum AS, Stallings MC, Hewitt JK. Onset of regular cannabis use and adult sleep duration: Genetic variation and the implications of a predictive relationship. Drug Alcohol Depend. 2019; 204: 107517. doi: 10.1016/j.drugalcdep.2019.06.019.

  37. Waliul Hasnat S, Waliul Hasnat S Jr. Amotivational syndrome. Slideshares. Available in: https://es.Slide share.net/WaliulHasnat/amotivational-syndrome.

  38. Arnold JC. Handbook of cannabis and related pathologies. Cambridge: Academic; 2017.

  39. Crane M. Dangers of cannabis: long term effects of pot on the brain and body. Estados Unidos: American Addiction Centers, Editorial; 2020.

  40. Meier MH, Caspi A, Danese A et al. Associations between adolescent cannabis use and neuropsychological decline: a longitudinal co-twin control study. Addiction. 2018; 113 (2): 257-265. doi: 10.1111/add.13946.

  41. Substance Abuse Center for Behavioral Health Statistics and Quality. Results from the 2018 National Survey on Drug Use and Health: Detailed Tables. SAMHSA. Available in: www.samhsa.gov/data/ report/2018-nsduh-detailed-tables.

  42. NIDA. Drug facts. National Institute on Drug Abuse; National Institutes of Health; U.S. Department of Health and Human Services. December 2019.

  43. NIDA Notes. How does Cannabis use affect school, work, and social life? [Acceso junio de 2020]. Available in: www.Drug.abuse.gov/news-events/nida-notes.

  44. Bassir Nia A, Medrano B, Perkel C, Galynker I, Hurd YL. Psychiatric comorbidity associated with synthetic cannabinoid use compared to cannabis. J Psychopharmacol. 2016; 30 (12): 1321-1330.

  45. Weinstein AM, Rosca P, Fattore L, London ED. Synthetic cathinone and cannabinoid designer drugs pose a major risk for public health. Front Psychiatry. 2017; 8: 156. doi: 10.3389/fpsyt.2017.00156.

  46. De Luca MA, Fattore L. Therapeutic use of synthetic cannabinoids: still an OpenIssue? Clin Ther. 2018; 40 (9): 1457-1466. doi: 10.1016/j.clinthera.2018.08.002.

  47. Miliano C, Margiani G, Fattore L, De Luca MA. Sales and advertising channels of new psychoactive substances (NPS): internet, social networks, and smartphone apps. Brain Sci. 2018; 8 (7): 123.

  48. Ruiz P, Strain EC, Lowinson JH. Lowinson and Ruiz's substance abuse: a comprehensive textbook. 5th ed. Philadelphia: Lippincott Williams & Wilkins Health; 2011.

  49. Jafari S, Tang T. Clinical diagnosis and treatment of cannabis dependence. BCMJ. 2016; 58 (6): 315-317.

  50. Nielsen S, Gowing L, Sabioni P, Le Foll B. Pharmacotherapies for cannabis dependence. Cochrane Database Syst Rev. 2019; 1 (1): CD008940. doi: 10.1002/14651858.CD008940.pub3.

  51. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th edition (DSM-5). Arlington, VA: American Psychiatric Association; 2013.

  52. Souza y MM et al. Psychiatric clinical history encoded for addiction, HCPCA. In: Alonso Lanza JL. Electronic medical history: ideas, experiences and reflections. 2014. Available in: http://bvs.sld.cu/revistas/ aci/vol13_5_05/aci02505.htm.

  53. Souza y MM. Evaluación clínica del paciente adicto al paciente. J. electrónico de medicina neuropsicológica. REMN. 2013; 14 (2): 455-468.

  54. NIAAA. National Institute on Alcohol Abuse and Alcoholism. Motivational enhancement therapy: A clinical research guide for therapists treating individuals with alcohol abuse and dependence. 2015. Available in: http://pubs.niaaa.nih.gov/publications/ProjectMatch/match02.pdf.

  55. Encuesta Nacional de Consumo de Drogas, Alcohol y Tabaco, ENCODAT 2016-2017. 28 de noviembre de 2017 [Acceso junio de 2020].

  56. Souza y MM. Desde la resiliencia hasta la reinserción social del paciente dual. Seminario "Prevención y rehabilitación de las adicciones". Máster en Psicoterapia de Las Adicciones. Colegio Internacional de Educación Superior, CIES/SEP. México, D.F. 31 de mayo de 2015.

  57. NIDA. National Institute on Mental health. Principles of drug addiction treatment: a research-based guide. 3rd edition. 2018. Available in: www.drugabuse.gov/publications/prin ciples-drug-addiction-treatment-research-based-guide-third-edition/drug-addiction-treatment-in-united-states

  58. Vanderplasschen W, Colpaert K, Autrique M et al. Therapeutic communities for addictions: a review of their effectiveness from a recovery-oriented perspective. ScientificWorldJournal. 2013; 2013: 427817. doi: 10.1155/2013/427817.

  59. NIDA NIH, SAMHSA. Principles of drug addiction treatment. A research-based guide 3rd ed. NIH Publication No. 12-4180 Printed & Revised December 2012.

  60. Prevention-Addiction Policy Forum. What Is Prevention. Available in: https://www.addictionpolicy.Org./ prevention.

  61. NIDA. Treating Criminal Justice-Involved Drug Abusers and Addicted Individuals. Principles of drug abuse treatment for criminal justice populations: a research-based guide. National Institute on Drug Abuse; 2018.

  62. DrugFacts can also be found in Preventing Drug Use among Children and Adolescents, A Re-search-Based Guide for Parents, Educators, and Community Leaders. 2nd edition. National Institute on Drug Abuse; 2003.

  63. NIDA. Lessons from Prevention Research. www.drugabuse.gov/publications/drugfacts/less sons-prevention-research. Revised March 2014. National Institute on Drug Abuse; National Institutes of Health; U.S. Department of Health and Human Services. updated March 2014.

  64. GHO. Global Health Observatory data, Resources for the prevention and treatment of substance use disorders. 2016. Available in: www.who.int/gho/substance_abuse/en/

  65. ONDCP Office of National Drug Control Policy. Cannabis Resource Center: www.whitehouse. gov/ondcp/Cannabis info, 2016.

  66. Souza y MM. Trastorno inducido por el Cannabis y otros trastornos mentales. XXV Congreso Nacional y V Congreso Internacional "Psiquiatría en salud mental: neurociencias, psiquiatría clínica y socio-comunidad". Asociación Mexicana de Psiquiatría, A.C. Mérida, Yucatán. 16-20 de noviembre de 2017.

  67. Souza y MM. Abuso infantil y violencia sexual en la sociedad actual. Psiquiatría APM J. 2015; 2 (3): 28-38.




2020     |     www.medigraphic.com